Engineered T-cells for personalized cancer therapy
Acute myeloid leukemia (AML) is a common blood cancer. Currently available therapy includes chemotherapy and allogeneic hematopoietic cell transplantation all of which have severe side effects. Recent development in cell-based immunotherapies, in particular modular, switchable chimeric antigen receptor (CAR) T cells are a promising route towards personalized cancer therapy. This novel therapeutic strategy offers the unique possibility to combine controllable CAR therapy, radioimmunotherapy and in vivo imaging in one single approach.
The Arndt/Fasslrinner lab is developing controllable living drugs, targeted radioimmunotherapy and in vivo imaging tools to design powerful personalized cancer therapy that is able to further optimize current treatment options for AML patients. Claudia Arndt, an expert in T cell and antibody engineering, significantly contributed
to the preclinical development of the adaptor CAR T cell technology “UniCAR”.
CD123-directed UniCAR T cells are currently tested in a phase I trial
(NCT04230265). Frederick Faßlrinner is a hematologist with profound expertise
in allogenic hematopoietic cell transplantation. His research focuses on
optimizing conditioning regimen before allogenic hematopoietic cell
transplantation e.g. by implementing reduced intensity approaches, addition of
radioimmunotherapy and cell-based immunotherapy.
- Implementation of allogeneic UniCAR T cell therapy as chemotherapy-free conditioning regimen before allogeneic hematopoietic stem cell therapy
- Visualization of allogeneic UniCAR T cell therapy and AML targets by in vivo PET imaging
- Combination of radioimmunotherapy with allogeneic UniCAR T cell therapy
LAB MEMBERS
© UKD
Group leader
NameDr. Claudia Arndt
|
POSITIONS |
|
|---|---|
| since 2020 | Mildred-Scheel-Nachwuchszentrum (MSNZ) research group leader and staff scientist at Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research |
| 2015-2020 | Postdoc at the Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research |
| EDUCATION | |
|---|---|
| 2010-2014 | Doctorate in Tumor Immunology, Institute of Immunology, Technical University Dresden, Germany |
| 2005-2010 | Study of Biology, Technische Universität Dresden, Dresden |
|
HONORS |
|
|---|---|
| 2019 | American Society of Immunotherapy in Cancer (SITC), Young Investigator Award |
| 2018 | One-site funding German Cancer Consortium (20.000 €) |
| 2010 | Ehrenfried Walter von Tschirnhaus certificate (top graduate, Technical University Dresden) |
MEMBERSHIPS
since 2015 German Society of Immunology (DGfI)
| FUNDINGS | |
|---|---|
| 2019-2022 | NCT Dresden-Translational Research Grant in Precision Oncology |
SELECTED PUBLICATIONS
Arndt C, Feldmann A, Koristka S, Schäfer M, Bergmann R, Mitwasi N, Berndt N, Bachmann D, Kegler A, Schmitz M, Puentes-Cala E, Soto JA, Ehninger G, Pietzsch J, Liolios C, Wunderlich G, Kotzerke J, Kopka K, Bachmann M. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. OncoImmunology. 2019;8:11.
Fasslrinner F, Arndt C (co-first authors), Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukemia. Br J Haematol. 2019;186(5):735-740.
Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014;28(1):59-69.
Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, Bachmann M. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013;27(4):964-7.
for complete publication record see ORCID
© UKD
Advanced Clinician Scientist
NameDr. med. Frederick Faßlrinner
|
POSITIONS |
|
|---|---|
| since 2020 | Mildred-Scheel-Nachwuchszentrum (MSNZ) research group leader at Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research |
| 2018-2020 | Clinician Scientist fellow Else Kröner-Forschungskolleg, TU Dresden Dresden |
| since 2014 | Resident Hematology/Oncology, Department of Internal Medicine I, University Hospital Dresden |
| 2013-2014 | Resident Pediatric Surgery, Medical School Hannover (MHH) |
EDUCATION/ CLINICALTRAINING
| 2015-2018 | Master of Clinical Research (M.Sc.), Dresden International University, Germany and Havard T.H. Chan School of Public Health, Boston, USA |
| 2011-2013 | Doctorate in Internal Medicine (Dr. med.), Medical Faculty Carl Gustav Carus, Technical University Dresden |
| 2005-2013 |
University Studies, Medicine Preparatory year: Mc Daniel College, Budapest, Hungary Preclinical part: Georg-August University Göttingen, Germany Clinical part: Technical University Dresden, Germany Erasmus stay: Universidad Autonoma de Madrid, Madrid, Spain |
|
HONORS |
|
|---|---|
| 2017 | Stipend for the Clinician Scientist program of the Else Kröner-Fresenius-Stiftung |
| 2017 | Stipend for the “Förderakademie” of the German Society of Internal Medicine (DGIM) |
| 2015 | Stipend for the Master of Clinical Research at the DIU, University Hospital Dresden, Technical University Dresden |
MEMBERSHIPS
2017 German Society of Internal Medicine (DGIM)
2018 European Society of Hematology and Oncology (EHA)
| FUNDINGS | |
|---|---|
| 2019 | MeDDrive Grant/Technical University Dresden (Targeting des tumorassoziierten Antigens „fms-like“ Tyrosinkinase 3 (FLT-3) mit dem UniCAR System: präklinische Evaluation humanisierter IgG4-basierter Antikörperderivate zur Therapie der akuten myeloischen Leukämie) |
SELECTED PUBLICATIONS
Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M. RRadioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. Biol Blood Marrow Transplant. 2019;S1083-8791(19)30747-5.
Fasslrinner F, Arndt C (co-first authors), Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukemia. Br J Haematol. 2019;186(5):735-740.
Fasslrinner F, Schetelig J, Burchert A Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematology 2018;5(4):e161-e169
for complete publication record see ORCID
© UKD
MD-student
NameJohannes Peschke
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).
© UKD
Biological lab assistant
NameKim Julia Weiße
© UKD
Biological lab assistant
NameLuisa Zimmermann
SELECTED PUBLICATIONS
Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. Biol Blood Marrow Transplant. 2019;S1083-8791(19)30747-5.
Arndt C, Feldmann A, Koristka S, Schäfer M, Bergmann R, Mitwasi N, Berndt N, Bachmann D, Kegler A, Schmitz M, Puentes-Cala E, Soto JA, Ehninger G, Pietzsch J, Liolios C, Wunderlich G, Kotzerke J, Kopka K, Bachmann M. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. OncoImmunology. 2019;8:11.
Fasslrinner F, Arndt C (co-first authors), Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukemia. Br J Haematol. 2019;186(5):735-740.
Fasslrinner F, Schetelig J, Burchert A Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematology 2018;5(4):e161-e169
LINKS
Helmholtz Zentrum Dresden Rossendorf
CONTACT
© UKD
Arndt/Faßlrinner lab
Besuchsadresse:
Universitätsklinikum Carl Gustav Cars Dresden, Technische Universität Dresden, Haus 31, Erdgeschoss, 016 Fetscherstrasse 74
01307 Dresden
Postadresse:
Technische Universität Dresden
Helmholtz-Zentrum Dresden-Rossendorf
Institute of Radiopharmaceutical Cancer Research
Gruppe Arndt/Faßrlinner
Bautzener Landstrasse 400
01328 Dresden